Carregant...
CAR T-cell immunotherapy of B-cell malignancy: the story so far
Chimeric antigen receptor (CAR) T-cell immunotherapy has achieved unprecedented efficacy in the treatment of chemotherapy-resistant or refractory B-cell malignancies. Promising results from pivotal anti-CD19 CAR T-cell phase II trials have led to landmark approvals of two CD19-specific CAR T-cell pr...
Guardat en:
| Publicat a: | Ther Adv Vaccines Immunother |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7257863/ https://ncbi.nlm.nih.gov/pubmed/32524070 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2515135520927164 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|